← 返回

增强型 NK 细胞联合 ONC201 或 ONC206 靶向侵袭性 K27M 脑肿瘤的联合治疗

英文原题:Combination therapy of supercharged NK cells and ONC201 or ONC206 to target aggressive K27M brain tumor.

查看英文原题

Combination therapy of supercharged NK cells and ONC201 or ONC206 to target aggressive K27M brain tumor.

PubMed 2025/01/01(内容时间) Crit Rev Immunol Q4 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

高级别胶质瘤是儿童患者常见的死亡原因。K27M细胞系常用作弥漫性内生型脑桥胶质瘤(DIPG)的肿瘤模型,因为其组蛋白H3蛋白中的赖氨酸被甲硫氨酸替代。本研究旨在阐明超活化NK(sNK)细胞单用或联合ONC201、ONC206靶向这类侵袭性儿童脑肿瘤K27M的作用。与原代IL-2活化NK细胞相比,sNK细胞分泌的IFN-γ更多;联合ONC201或ONC206进一步提高了sNK细胞的IFN-γ水平。以原代NK细胞或sNK细胞作为效应细胞攻击胶质瘤K27M细胞系时,肿瘤细胞对sNK细胞介导的细胞毒作用更敏感。sNK细胞联合ONC201或ONC206后,对K27M的细胞毒作用显著增强。本研究提示,sNK细胞单用或联合ONC201、ONC206可能成为治疗和预防侵袭性儿童脑肿瘤复发的策略。

展开英文摘要原文

High-grade glioma tumors are the common cause of death in pediatric patients. K27M cell line is regularly used as tumor model to study diffuse intrinsic pontine glioma (DIPG) since they harbor genetic mutation in which the lysine of the histone H3 protein is replaced with a methionine. The objective of this study is to demonstrate the significance of supercharged NK (sNK) cells alone or in combination with ONC201 or ONC206 to target such aggressive pediatric brain tumor K27M.

We have observed increased secretion of IFN- by sNK cells compared to primary IL-2-activated NK cells. Combining sNK cells with ONC201 or ONC206 further increased IFN- in sNK cells. When primary NK cells and sNK cells were used as effectors against the glioma tumor cell line K27M, tumor cells were found to be highly susceptible to sNK cell-mediated cytotoxicity compared to primary NK cell-mediated cytotoxicity. sNK cell-mediated cytotoxicity against K27M was significantly increased when sNK cells were combined with ONC201 and ONC206.

This study suggests the potential use of sNK cells alone or in combination with ONC201 or ONC206 as therapeutic strategies in treating and preventing the recurrence of aggressive pediatric brain tumors.

论文信息

作者
Kaur K、Jewett A
第一作者单位
Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, 90095 Los Angeles, CA, USA.United States
通讯作者单位
Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, 90095 Los Angeles, CA, USA; The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, Los Angeles, CA, USA.United States
文献类型
综述
期刊
Critical reviews in immunology2025
原文标识
PubMed 40460384 · DOI 10.1615/CritRevImmunol.2025058345